BioWa, OBT in Potelligent Technology license agreement
Under the agreement, OBT will use Potelligent Technology for the manufacturing, development and commercializing chosen ADCC programs from its pipeline of preclinical antibodies for oncology, which it has
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.